Democrats’ drug pricing plan, while scaled back, could still squeeze pharma top-sellers

Legislation backed by President Joe Biden and top Democratic lawmakers would allow for price negotiation on up to 20 older drugs, potentially impacting blockbusters from Pfizer, Bristol Myers Squibb and others.